The DrugBank accession number for axitinib, a small molecule tyrosine kinase inhibitor developed by Pfizer, is DB08854 [1].
What else is known about axitinib?
Axitinib is a targeted therapy approved for adults with advanced renal cell carcinoma (RCC) that has progressed after treatment with at least one prior systemic therapy [2]. It works by inhibiting vascular endothelial growth factor receptors (VEGFRs), which are involved in tumor blood vessel formation [2].
When did axitinib receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved axitinib (Inlyta) in January 2012 for the treatment of advanced renal cell carcinoma [3].
How does axitinib's patent status look?
Information regarding axitinib's patent status, including expiry dates and any ongoing litigation, can be found on DrugPatentWatch.com [4]. Patent information is crucial for understanding when generic versions of the drug might become available.
Who are axitinib's main competitors in RCC treatment?
Other targeted therapies and immunotherapies are used to treat advanced RCC. These include drugs like sunitinib, pazopanib, and nivolumab, each with different mechanisms of action and efficacy profiles [3].
What are the common side effects of axitinib?
Common side effects reported in patients treated with axitinib include diarrhea, hypertension, fatigue, decreased appetite, nausea, and hoarseness [2]. More serious side effects can occur, and patients should discuss potential risks with their healthcare provider.
How is axitinib administered?
Axitinib is taken orally, typically twice a day [2].
What is the typical pricing for axitinib?
The cost of axitinib can vary based on insurance coverage, pharmacy, and dosage. Patients often explore patient assistance programs offered by the manufacturer or seek information from insurance providers for detailed pricing [4].
What clinical trials have been conducted for axitinib?
Key clinical trials have evaluated axitinib's efficacy and safety in patients with advanced RCC. The main trial leading to its approval, the AXIS trial, compared axitinib to sorafenib in patients who had previously received treatment for advanced RCC [3].
What are the risks associated with axitinib treatment?
Beyond common side effects, axitinib carries risks of serious adverse events, including cardiovascular problems, bleeding, impaired wound healing, and thyroid dysfunction [2]. Patients undergo regular monitoring for these potential issues.
*
**Cited Sources:
1. https://go.drugbank.com/drugs/DB08854
2. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/information-about-drug-products-approved-may-2012
3. https://www.nejm.org/doi/full/10.1056/NEJMoa1113510
4. https://drugpatentwatch.com/